PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.18%
G&A reduction while AXSM shows 0.00% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.18%
Operating expenses reduction while AXSM shows 6.62% growth. Joel Greenblatt would examine advantage.
-25.18%
Total costs reduction while AXSM shows 8.31% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
25.18%
EBITDA growth 50-75% of AXSM's 35.57%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
25.18%
Operating income growth 50-75% of AXSM's 35.57%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
-25.18%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.66%
Tax expense reduction while AXSM shows 0.00% growth. Joel Greenblatt would examine advantage.
14.66%
Similar net income growth to AXSM's 19.26%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
14.77%
EPS growth 50-75% of AXSM's 20.49%. Martin Whitman would scrutinize operations.
14.77%
Diluted EPS growth 50-75% of AXSM's 20.49%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.